The city of Jacksonville, Florida, currently has 5 active clinical trials seeking participants for Ulcerative Colitis research studies.
A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis
Recruiting
A study to investigate bowel urgency in adults with moderately to severely active ulcerative colitis (UC) treated with mirikizumab. The study will have 4 periods and will last for 36 weeks.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/17/2024
Locations: Encore Borland-Groover Clinical Research, Jacksonville, Florida
Conditions: Ulcerative Colitis, Ulcerative Colitis Chronic
A Phase 1b Proof-of-concept Trial Exploring the Effects of FE 999322 and FE 999324 in Adults With Mild to Moderate Ulcerative Colitis
Recruiting
To explore the safety of FE 999322 (microbiota suspension) and FE 999324 (microbiota capsule) versus placebo in subjects with active mild to moderate ulcerative colitis (UC).
Gender:
All
Ages:
18 years and above
Trial Updated:
05/30/2024
Locations: Ferring Investigational Site, Jacksonville, Florida
Conditions: Ulcerative Colitis
A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)
Recruiting
This study is designed to evaluate the long-term efficacy and safety of mirikizumab in participants with moderately to severely active ulcerative colitis (UC). The study will last up to 3 years. Participants who complete the 3-year study may continue to receive mirikizumab until it is (outside of this study) in their country or until they meet other discontinuation criteria.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
05/27/2024
Locations: Encore Borland-Groover Clinical Research, Jacksonville, Florida
Conditions: Ulcerative Colitis
Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission
Recruiting
The purpose of this study is to compare the effectiveness and safety of a strategy of switching to an alternative targeted immunomodulator (TIM) therapy to treat to a target of endoscopic remission, versus continuing index TIM in patients with inflammatory bowel disease (IBD) (Crohn's disease or ulcerative colitis [UC]) in symptomatic remission with moderate to severe endoscopic inflammation despite optimization of index TIM in a real-world setting.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/12/2024
Locations: Mayo Clinic Jacksonville, Jacksonville, Florida
Conditions: Ulcerative Colitis, Crohn Disease
A 5-year Longitudinal Observational Study of Patients Undergoing Therapy for Inflammatory Bowel Disease
Recruiting
TARGET-IBD is a 5-year, longitudinal, observational study of adult and pediatric patients (age 2 and above) being managed for Inflammatory Bowel Disease (IBD) in usual clinical practice. TARGET-IBD will create a research registry of patients with IBD within academic and community real-world practices in order to assess the safety and effectiveness of current and future therapies.
Gender:
All
Ages:
2 years and above
Trial Updated:
10/27/2023
Locations: University of Florida Health Jacksonville-Gastroenterology, Jacksonville, Florida
Conditions: Inflammatory Bowel Diseases, Crohn's Disease, Ulcerative Colitis, Indeterminate Colitis